Skip to content

Randomized controlled study of supplemented Banxia Baizhu Tianma Decoction combined with intermittent fasting in the intervention of Grade 1 obese hypertension

Randomized controlled study of supplemented Banxia Baizhu Tianma Decoction combined with intermittent fasting in the intervention of Grade 1 obese hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081594
Enrollment
Unknown
Registered
2024-03-06
Start date
2024-03-07
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Grade 1 obese hypertension

Interventions

treatment group:Supplemented Banxia Baizhu Tianma Decoction combined with intermittent fasting

Sponsors

Xiyuan Hospital of CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age range from 18 to 65 years old; (2) Meets the diagnostic criteria for primary hypertension, with grade 1 hypertension and 28kg/m2=BMI<35kg/m2; (3) Traditional Chinese medicine syndrome differentiation is consistent with the syndrome of phlegm dampness stagnation; (4) Have not taken antihypertensive drugs in the past or have not taken antihypertensive drugs regularly; (5) Sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Complicated with coronary heart disease, cerebrovascular disease, diabetes, heart failure, chronic renal insufficiency and other clinical diseases; (2) Suffering from obvious liver diseases or ALT and AST exceeding the normal upper limit by 2 times; The blood creatinine level is higher than the upper normal limit; (3) Secondary obesity, such as Cushing's syndrome, polycystic ovary syndrome, hypothalamic pituitary infection, hypothyroidism, insulinoma, tumors, trauma and other diseases causing obesity; (4) Severe mental illness patients, severe hematopoietic system diseases patients, malignant tumors, or patients with a life expectancy of less than 3 years; (5) Those with poor estimated compliance and poor likelihood of follow-up; (6) Individuals who have participated or are currently participating in other clinical trials within the past three months; (7) Suspected or clearly allergic individuals to experimental drugs, as well as individuals with allergic constitutions or allergies to multiple drugs; (8) Pregnant or preparing pregnant women, lactating women.

Design outcomes

Primary

MeasureTime frame
Clinic blood pressure;

Secondary

MeasureTime frame
24 hours ambulatory blood pressure;body mass index;Family self-test blood pressure;Quantitative integration of hypertension symptom grading;blood lipids;Safety indicators;

Countries

China

Contacts

Public ContactYuerong Jiang

Xiyuan Hospital of CACMS

jiang_yuerong@163.com+86 62835923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026